以Matrix-M™为佐剂的病毒载体疟疾疫苗异源初免-加强免疫的安全性和免疫原性
这项开放标签、首次人体、对照的I期研究评估了以Matrix-M为佐剂、编码ME-TRAP抗原的ChAd63初免和8周后MVA加强的异源初免-加强方案的安全性和免疫原性。22名健康成人分别接种ChAd63-MVA ME-TRAP单独疫苗(n=6)或加25μg(n=8)或50μg(n=8)Matrix-M佐剂。接种总体安全且耐受良好,加佐剂未增加局部反应原性但全身不良事件报告更频繁,各佐剂组与对照组在各时间点的细胞和体液免疫原性无差异。
要点
- ChAd63-MVA ME-TRAP异源初免-加强接种总体安全且耐受良好,多数局部和全身不良事件为轻度。
- 加Matrix-M佐剂未增加局部反应原性,但佐剂组志愿者报告的全身不良事件比对照组更频繁。
- T细胞ELISpot反应在MVA加强后7天达峰,TRAP特异性IgG在加强后28天最高,各佐剂组与对照组间无差异。
核心结论
- Matrix-M可安全地与ChAd63-MVA ME-TRAP异源初免-加强免疫联合使用,且不降低细胞或体液免疫原性。
研究设计与样本
- 开放标签、首次人体、对照的I期研究,22名健康成人肌内接种ChAd63-MVA ME-TRAP单独疫苗(n=6)或加25μg(n=8)或50μg(n=8)Matrix-M佐剂,ChAd63初免后8周以MVA加强。
主要发现
- 接种总体安全且耐受良好,多数局部和全身不良事件为轻度。
- 加Matrix-M未增加局部反应原性,但佐剂组志愿者报告的全身不良事件比对照组更频繁。
- T细胞ELISpot反应在MVA ME-TRAP加强后7天达峰,TRAP特异性IgG在加强后28天最高,三组均如此。
- 各时间点佐剂组与对照组之间的细胞和体液免疫原性无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of viral vectors in heterologous prime-boost regimens to induce potent T cell responses in addition to humoral immunity is a promising vaccination strategy in the fight against malaria. We conducted an open-label, first-in-human, controlled Phase I study evaluating the safety and immunogenicity of Matrix-M adjuvanted vaccination with a chimpanzee adenovirus serotype 63 (ChAd63) prime followed by a modified vaccinia Ankara (MVA) boost eight weeks later, both encoding the malaria ME-TRAP antigenic sequence (a multiple epitope string fused to thrombospondin-related adhesion protein). Twenty-two healthy adults were vaccinated intramuscularly with either ChAd63-MVA ME-TRAP alone (n=6) or adjuvanted with 25μg (n=8) or 50μg (n=8) Matrix-M. Vaccinations appeared to be safe and generally well tolerated, with the majority of local and systemic adverse events being mild in nature. The addition of Matrix-M to the vaccine did not increase local reactogenicity; however, systemic adverse events were reported more frequently by volunteers who received adjuvanted vaccine in comparison to the control group. T cell ELISpot responses peaked at 7-days post boost vaccination with MVA ME-TRAP in all three groups. TRAP-specific IgG responses were highest at 28-days post boost with MVA ME-TRAP in all three groups. There were no differences in cellular and humoral immunogenicity at any of the time points between the control group and the adjuvanted groups. We demonstrate that Matrix-M can be safely used in combination with ChAd63-MVA ME-TRAP heterologous prime-boost immunization without any reduction in cellular or humoral immunogenicity. Clinical Trials Registration NCT01669512.
引用
- Venkatraman N, Anagnostou N, Bliss C, et al. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. Vaccine. 2017. PMID: 28941620. doi:10.1016/j.vaccine.2017.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。